Literature DB >> 12455056

Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo.

Lianhua Bai1, Philipp Beckhove, Markus Feuerer, Viktor Umansky, Carmen Choi, Florian Schütz Erich-Franz Solomayer, Ingo J Diel, Volker Schirrmacher.   

Abstract

Dendritic cells (DC) and T cells were generated from Ficoll separated bone marrow (BM) mononuclear cells of primary operated breast cancer patients according to new cell culture protocols. BM-DC were capable of functioning as professional antigen-presenting cells (APCs) and of inducing autologous antigen-specific memory T-cell responses to either tetanus toxoid recall antigen or to breast cancer antigens. Treatment with lipopolysaccharide (LPS) resulted in phenotypic and functional maturation of BM-DC. When BM-DC, pulsed with breast cancer-associated tumor antigens, were cocultured with autologous patient-derived BM-T cells to allow for cognate breast cancer antigen recognition and stimulation, apoptosis of T cells-which occurred in noncognate coculture systems-was inhibited. Furthermore, in cocultures allowing for antigen-specific cognate interactions, the expression on BM-DC of CD83, MHC class II, CD40 and CD86 molecules was upregulated and the cytokines IL-12 and IFN-alpha were produced in significantly elevated amounts. Adoptive transfer of breast cancer-reactive memory T cells together with APCs into human breast cancer-bearing NOD/SCID mice caused a regression of the tumor and prolonged survival of the animals. This was not the case when such animals had been treated by transfer of reactivated BM T cells without BM-DCs. Our findings suggest that cognate interactions between cancer patient-derived memory BM-T cells and tumor antigen-presenting BM-DCs are important for reciprocal cell stimulation, survival and therapeutic activity. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12455056     DOI: 10.1002/ijc.10781

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Bone marrow vaccination: a novel approach to enhance antigen specific antitumor immunity.

Authors:  Stephanie Fresnay; Xiaoyu Zhang; Scott E Strome; Duane A Sewell
Journal:  Vaccine       Date:  2011-09-25       Impact factor: 3.641

2.  Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ.

Authors:  Moritz Koch; Philipp Beckhove; Jan Op den Winkel; Daniel Autenrieth; Philipp Wagner; Daniel Nummer; Sebastian Specht; Dalibor Antolovic; Luis Galindo; Friedrich H Schmitz-Winnenthal; Volker Schirrmacher; Markus W Büchler; Jürgen Weitz
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

3.  Significance of heparanase in cancer and inflammation.

Authors:  Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin
Journal:  Cancer Microenviron       Date:  2011-08-03

Review 4.  Cooperativity of adaptive and innate immunity: implications for cancer therapy.

Authors:  Anil Shanker; Francesco M Marincola
Journal:  Cancer Immunol Immunother       Date:  2011-06-09       Impact factor: 6.968

Review 5.  Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy.

Authors:  Christoph Domschke; Andreas Schneeweiss; Stefan Stefanovic; Markus Wallwiener; Joerg Heil; Joachim Rom; Christof Sohn; Philipp Beckhove; Florian Schuetz
Journal:  Breast Care (Basel)       Date:  2016-04-27       Impact factor: 2.860

6.  Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors.

Authors:  Philipp Beckhove; Markus Feuerer; Mathias Dolenc; Florian Schuetz; Carmen Choi; Nora Sommerfeldt; Jochen Schwendemann; Katrin Ehlert; Peter Altevogt; Gunther Bastert; Volker Schirrmacher; Viktor Umansky
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

7.  GK-1 improves the immune response induced by bone marrow dendritic cells loaded with MAGE-AX in mice with melanoma.

Authors:  Gabriela Piñón-Zárate; Miguel Ángel Herrera-Enríquez; Beatriz Hernández-Téllez; Katia Jarquín-Yáñez; Andrés Eliú Castell-Rodríguez
Journal:  J Immunol Res       Date:  2014-10-29       Impact factor: 4.818

8.  Targeting specificity of dendritic cells on breast cancer stem cells: in vitro and in vivo evaluations.

Authors:  Sinh Truong Nguyen; Huyen Lam Nguyen; Viet Quoc Pham; Giang Thuy Nguyen; Cuong Do-Thanh Tran; Ngoc Kim Phan; Phuc Van Pham
Journal:  Onco Targets Ther       Date:  2015-01-30       Impact factor: 4.147

Review 9.  Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.

Authors:  Volker Schirrmacher; Stefaan van Gool; Wilfried Stuecker
Journal:  Biomedicines       Date:  2019-08-30

10.  High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow.

Authors:  J Joseph Melenhorst; Phillip Scheinberg; Pratip K Chattopadhyay; Emma Gostick; Kristin Ladell; Mario Roederer; Nancy F Hensel; Daniel C Douek; A John Barrett; David A Price
Journal:  Blood       Date:  2008-11-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.